Real-time SEC alerts Start Free →
Profitelligence
Dexcom Inc.
DXCM MEDIUM Impact

Dexcom Inc.

Dexcom Reports Preliminary Q4 and FY 2025 Results, Provides FY 2026 Outlook

| 8-K |Healthcare

Summary

Dexcom, Inc. announced preliminary, unaudited financial results for the fourth quarter and full fiscal year 2025, reporting total revenue of approximately $1.260 billion for Q4 and $4.662 billion for FY 2025, with growth rates of 13% and 16% respectively. The company also provided an initial outlook for fiscal year 2026, anticipating total revenue between $5.16 - $5.25 billion, representing expected growth of approximately 11-13% over 2025. Non-GAAP Gross Profit Margin and Non-GAAP Operating Margin guidance for 2026 was also provided.

Profitelligence Profitelligence Alerts

Get alerts for DXCM

Be first to know when Dexcom Inc. files with the SEC.

Set Up Alerts →

Filing Categories

Earnings Beat General Statement Financial Instrument Agreement

Advertisement

About Dexcom Inc.

Dexcom Inc. is a prominent player in the medical technology sector, specializing in continuous glucose monitoring (CGM) systems for diabetes management. The company's primary function is to develop and distribute innovative CGM devices that provide real-time glucose readings, allowing individuals with diabetes to make informed decisions about their health. Dexcom’s products play a critical role in healthcare by offering an alternative to traditional fingerstick testing, thus improving quality of life for many users. The company impacts several sectors, most notably within healthcare and technology, by integrating advanced data analytics and wireless technology into its monitoring systems. This not only aids individuals in managing their glucose levels but also supports healthcare providers in delivering better patient care through data-driven insights. In the financial market, Dexcom Inc. is recognized for its contributions to the growing field of digital health solutions. The company has established itself as a leader in its niche, continuously pushing the boundaries of technology to offer more precise and user-friendly glucose monitoring options. Founded in 1999 and headquartered in San Diego, California, Dexcom remains at the forefront of diabetes management solutions.

Exchange: NASDAQ Industry: Medical Devices Company Website →

Official SEC Documents

DXCM
DXCM Research
8Ks, insider trades, financials, technicals
SEC Alert Manager
Get alerts within 60 seconds of new filings

Advertisement